Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

Alireza Eghtedar, Srdan Verstovsek, Zeev Estrov, Jan Burger, Jorge Cortes, Carol Bivins, Stefan Faderl, Alessandra Ferrajoli, Gautam Borthakur, Solly George, Peggy A. Scherle, Robert C. Newton, Hagop M. Kantarjian, Farhad Ravandi

Blood (2012) 119 (20): 4614–4618.

https://doi.org/10.1182/blood-2011-12-400051

Published: 2012

Journal Articles

Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)

Alireza Eghtedar, MD, Srdan Verstovsek, MD, PhD, Jorge E. Cortes, MD, Zeev Estrov, MD, Jan A. Burger, MD, PhD, Carol Bivins, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Solly George, RN, Robert Newton, PhD, Hagop Kantarjian, MD, Farhad Ravandi, MD

Blood (2010) 116 (21): 509.

https://doi.org/10.1182/blood.V116.21.509.509

Published: 2010

Journal Articles

Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients.

Gautam Borthakur, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, Marina Konopleva, MD, PhD, Jan A. Burger, MD, PhD, Deborah A. Thomas, MD, Tapan Kadia, MD, Betsy Williams, RN, Solly George, Hagop Kantarjian, MD

Blood (2009) 114 (22): 1053.

https://doi.org/10.1182/blood.V114.22.1053.1053

Published: 2009

Journal Articles

Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study.

Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Zeev Estrov, MD, Jan A. Burger, MD, PhD, Solly George, Rn, Carol Bivins, Rn, Jorge Cortes-Franco, MD, William M Garrett, MBA, Robert C Newton, PhD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 631.

https://doi.org/10.1182/blood.V114.22.631.631

Published: 2009

Journal Articles

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

Gautam Borthakur, MD, Zeev Estrov, Guillermo Garcia-Manero, MD, Betsy Williams, Jay K. Wathen, Marina Konopleva, Jan Burger, Alessandra Ferrajoli, Solly George, Hagop Kantarjian

Blood (2008) 112 (11): 2985.

https://doi.org/10.1182/blood.V112.11.2985.2985

Published: 2008

Journal Articles

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Francis Giles, MD, David A. Rizzieri, MD, Solly George, RN, Wendy Stock, MD, Jeannie Fontanilla, BS, Gavin S. Choy, PharmD, Gregory I. Berk, MD

Blood (2006) 108 (11): 1968.

https://doi.org/10.1182/blood.V108.11.1968.1968

Published: 2006

NARROW

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)

Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients.

Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study.

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)

Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients.

Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study.

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only